Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones – Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, and an interim data update is expected in...
Sutro Biopharma
310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412
